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Metformin and abdominal aortic aneurysm 
R.J. Hinchliffe  
Recently published data from a number of sources appear to suggest that the oral hypoglycaemic 
agent metformin may prevent abdominal aortic aneurysm (AAA) development, attenuate growth 
and, perhaps even prevent rupture. Previous studies have hinted that hypoglycaemic agents might 
reduce AAA expansion.1  The latest data, specific to metformin are compelling. Metformin is a 
biologically plausible drug since it has a wide range of effects on inflammation and metabolism. 
Although potentially exciting observations they remain preliminary and should be interpreted with 
some caution.  
Although AAA and ruptured AAA appear to be declining (lifestyle and waning smoking habits), the 
widespread adoption of regional and national screening programmes continues to identify large 
numbers of men (and some women) with small AAA. In the UK this amounts to 3-4,000 new cases 
per year enrolled in to ultrasound surveillance as part of the national screening programme. The 
growth rates of these AAA and consequently the proportion reaching threshold for surgery haven’t 
changed in the past 25 years.2  
Methods to reduce AAA related mortality have recently focussed on screening and improving the 
outcomes from surgery. Multi-modal quality improvement programmes for surgery and refining new 
technology to increase the applicability and improve the durability of endovascular repair have been 
central in surgeons’ minds. These are expensive approaches and significantly impact upon patients’ 
quality of life.  
Interventions that retard the growth of or reduce the risk of rupture represent could represent an 
additional opportunity to reduce AAA related mortality in screening programmes. This is particularly 
appealing since contemporary data appear to suggest that AAA diameter at rupture may be larger 
than previously thought (8.4cm in the IMPROVE Trial).3 There are other potential advantages of an 
intervention that reduces aortic growth.  AAA diameter appears to be an independent risk factor for 
subsequent cardiovascular and all-cause mortality.4 It is tempting to hypothesise therefore that 
attenuating aortic growth may save lives and reduce cardiovascular events.  
Unfortunately efforts to prevent AAA growth or rupture have largely proved futile. Smoking 
cessation appears to be effective. Therapies that have been encouraging in animal models and small-
scale trials have included a variety of anti-hypertensives, antibiotics and even anti-allergic drugs. 
These have all proven ineffective in larger well-constructed randomised studies.  
Observations that people with diabetes (5-6% of the adult population in Europe) are at lower risk of 
developing aneurysmal disease, progressing aneurysmal disease and rupture risk are well 
documented. Data from 17 population based studies were pooled and estimated that the odds of 
developing AAA in patients with diabetes are 0.80 (95% CI 0.70–0.90) compared to a non-diabetic 
population.5 At first sight these observations appear counter-intuitive. Around 15% of people with 
AAA have diabetes (predominantly type 2).  AAA have all the hallmarks of a systemic disease with 
many features in common with atherosclerosis and diabetes itself confers a two-fold excess risk of 
cardiovascular disease. There are a number of plausible biological explanations for this paradox that 
have been confirmed in animal models. Among them are that hyperglycaemia has the effect of 
attenuating medial elastolysis, macrophage infiltration and neovascularisation.6  
The observation in some RCTs of interventions for AAA growth suggest that diabetes is a very strong 
and independent negative predictor. In fact the effect size appears to be improbably large (>60% 
lower probability of aneurysm growth >5 mm) in some studies.7 Competing risks may be an 
explanation for these observations. The competing risks include premature deaths in people with 
diabetes from other causes, especially cardiovascular disease. An alternative explanation may be 
that key lifestyle and pharmacological interventions associated with the onset of diabetes reduce 
the risk. These are frequently delivered at the onset of (or even before) diabetes and in some 
countries such as the UK as part of a pay for performance program in primary care. Most notably 
these interventions include drugs to prevent and manage the microvascular and macrovascular 
complications of diabetes including lipid lowering therapy, angiotensin receptor blockade and anti-
platelet therapy. Importantly disease progression is monitored and adjusted frequently in people 
with diabetes.  
For most people who develop type 2 diabetes the first line treatment is with lifestyle modification in 
combination with the oral hypoglycaemic agent metformin. Metformin is a biguanide and works by 
decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. 
Biologically, it has pleiotropic anti-inflammatory effects on the vasculature, a biologically plausible 
approach in AAA. 8 
Since none of the currently available cardiovascular medications have proven effective in controlling 
AAA growth eyes have turned to alternative explanations. Experimental studies have demonstrated 
that some of these hypoglycaemic drugs have biological plausibility. Rosiglitazone, one of the family 
of thiozalinedones (Peroxisome proliferator-activated receptor gamma agonist (PPAR-γ)) was found 
to reduce aneurysm expansion and prevent rupture in a mouse model.9 Unfortunately, the side 
effect profile of these drugs meant they were never considered for in vivo studies. 
Data from a case control study in Taiwan supported the association of both metformin and 
thiozalinedones / sulphonylureas with lower risk of development of AAA.10 Moreover, those who 
had received the longest duration of metformin therapy were at lowest risk. In contrast alpha-
glucosidase and DPP-4 inhibitors appeared to have no effect.  
Golledge recently catalogued AAA growth rates in 3 separate Australasian cohorts.11 In the 1357 
(mean diameter 3.7cm) that were followed up with ultrasound over a mean of 3.6 years, the growth 
rates were significantly lower in those with diabetes taking metformin compared to those who were 
not taking metformin even after adjustment for other risk factors. Other diabetes medications did 
not appear to be associated with growth rates.  
In a study of 58 patients with diabetes and AAA from Stanford, USA, the effect of 11 drug therapies 
on AAA was examined. Metformin was the only medication associated with a negative effect on AAA 
enlargement and this effect was robust to adjustment of known confounders. The same group 
performed analysed the effect of metformin in a murine model (elastase) of AAA. They found that 
non-diabetic mice given metformin were less likely to develop AAA (40% v 100% in the control 
group). There was preservation of medial elastin and smooth muscle cells in the metformin group 
with a reduction in immune cell (macrophage, T and B cells) accumulation and neovessel  density. 12 
Metformin is an attractive drug that is now 60 years old. It has few drug interactions is cheap and 
well tolerated in people with and without diabetes. Gastrointestinal side effects occur in 10-20% of 
people but these effects appear to improve in most with appropriate dose titration. For many with 
diabetes the commencement of metformin is associated with an improvement in their overall 
symptoms and weight loss. There may be added benefits of a reduction in the incidence of 
cardiovascular events and cancer. It has been used for a variety of non-diabetes conditions including 
polycystic ovarian syndrome and is currently the subject of a number of RCTs in cardiovascular 
disease including heart failure. 
The observational data on the effect of metformin on AAA development and expansion are 
interesting. They could be explained away by a number of confounders or competing risks as 
suggested by a recent Danish study that failed to demonstrate any effect of metformin on ruptured 
AAA rates.13   
It is difficult to see how further observational studies will help answer the question of whether 
metformin will become a tool in the treatment of patients with AAA.  The next logical step is an 
appropriately powered randomised clinical trial of metformin in patients with AAA.  
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